Recent licensing deals and pipeline activity put Innoviva in focus

Innoviva (INVA) has drawn attention after two recent announcements: an exclusive licensing and distribution deal for its antibiotic XACDURO with Dr. Reddy’s Laboratories, and the separate launch of Nortiva Bio, a clinical-stage subsidiary built around the LYNX drug delivery platform.

At a share price of $22.49, Innoviva has eased slightly over the past week and day, but its year to date share price return of 13.19% and three year total shareholder return of 78.07% point to momentum that has built over a longer horizon, with the XACDURO licensing deal and Nortiva Bio launch likely shaping how investors weigh future growth prospects against risk.

If you want to see what else is gaining attention around healthcare and biotech, it is a good time to scan 40 healthcare AI stocks.

With Innoviva trading at $22.49 and screens flagging a mix of technical sell signals, yet data pointing to a 61% intrinsic discount and a 42% gap to the analyst target, is this a mispriced pipeline story, or is the market already baking in future growth?

Price-to-Earnings of 3.3x: Is it justified?

On simple headline numbers, Innoviva looks inexpensive, with the stock at $22.49 trading on a P/E of 3.3x while peers cluster much higher.

The P/E multiple compares the company’s share price to its earnings per share and is a common way investors think about what they are paying for current profitability. For a profitable biopharma company with products like RELVAR/BREO, ANORO, GIAPREZA and XACDURO, such a low P/E raises questions about how consistently those earnings can be converted to cash, particularly with high levels of non cash earnings and forecasts that point to declining profits over the next three years.

Relative to the US Pharmaceuticals industry average P/E of 14.9x and a peer average of 15.3x, Innoviva’s 3.3x multiple is far lower, suggesting the market is currently assigning a steep discount to its earnings. Even compared with an estimated fair P/E of 7.9x, the stock trades well below a level the market could potentially move toward if sentiment or visibility on its earnings profile changed.

Result: Price-to-Earnings of 3.3x (UNDERVALUED)

However, investors also have to weigh risks around the decline in net income growth of 22% and consider whether Innoviva can sustain or grow royalties as products mature and competition responds.

Another view on Innoviva: what the DCF model suggests

The low 3.3x P/E points one way, and our DCF model points the same way with a different lens, indicating Innoviva at $22.49 is trading 61% below an estimated future cash flow value of $57.69. That is a large gap, so is the market being too cautious, or are the cash flow assumptions too generous?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Innoviva for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mixed picture on Innoviva leaves you undecided, now is a good time to review the numbers yourself, weigh both sides, and assess the 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Innoviva?

If Innoviva has caught your attention, do not stop there. Use the Simply Wall St screener to spot other opportunities that could round out your portfolio.

• Target potential mispricings by scanning 45 high quality undervalued stocks that combine solid fundamentals with room for a rerating.
• Build resilience into your portfolio by reviewing 66 resilient stocks with low risk scores that score well on stability and downside protection.
• Get ahead of the crowd by checking the screener containing 19 high quality undiscovered gems before they sit on everyone else’s watchlist.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.